A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2.

被引：0
|
作者：
Gradishar, W. J. [1 ]
Krasnojon, D. [1 ]
Cheporov, S. [1 ]
Makhson, A. N. [1 ]
Manikhas, G. M. [1 ]
Clawson, A. [1 ]
Bhar, P. [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P5-19-13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-19-13
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
    Tamura, Kenji
    Inoue, Kenichi
    Masuda, Norikazu
    Takao, Shintaro
    Kashiwaba, Masahiro
    Tokuda, Yutaka
    Iwata, Hiroji
    Yamamoto, Naohito
    Aogi, Kenjiro
    Saeki, Toshiaki
    Nakayama, Takahiro
    Sato, Nobuaki
    Toyama, Tatsuya
    Ishida, Takanori
    Arioka, Hitoshi
    Saito, Mitsue
    Ohno, Shinji
    Yamauchi, Hideko
    Yamada, Kimito
    Watanabe, Junichiro
    Ishiguro, Hiroshi
    Fujiwara, Yasuhiro
    CANCER SCIENCE, 2017, 108 (05): : 987 - 994
  • [42] Outcome of patients treated with docetaxel versus paclitaxel in a non-randomized phase IV trial of first-line taxane/trastuzumab therapy in patients with HER2+metastatic breast cancer (MBC)
    Reddy, JC
    Barker, C
    Lim, D
    Klein, PM
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S129 - S129
  • [43] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.
    Beslija, S.
    Brodowicz, T.
    Greil, R.
    Inbar, M. J.
    Kahan, Z.
    Kaufman, B.
    Lang, I.
    Steger, G. G.
    Stemmer, S. M.
    Zielinski, C.
    Zvirbule, Z.
    CANCER RESEARCH, 2011, 71
  • [44] Navcap (vinorelbine and capecitabine) versus navcap followed by weekly docetaxel as first-line treatment in metastatic breast cancer patients: A randomized multicenter phase II trial
    Ghosn, M.
    Farhat, F. S.
    Kattan, J. G.
    Hanna, C.
    Younes, F.
    Haddad, N.
    Aftimos, P.
    Nasr, F.
    Moukadem, W.
    Chahine, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Preliminary clinical results of a randomized phase IIb study of weekly paclitaxel (PCT) ± trastuzumab (T) as first-line therapy of patients (pts) with HER-2/neu positive metastatic breast cancer (MBC).
    Gasparini, G
    Morabito, A
    De Sio, L
    Carillio, G
    Gion, M
    Zancan, M
    Rocco, S
    Crivellari, D
    Spada, A
    Veronesi, A
    Filippelli, G
    Silingardi, V
    Cognetti, F
    Papaldo, P
    Amadori, D
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S51 - S51
  • [46] Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
    Gradishar, William J.
    Krasnojon, Dimitry
    Cheporov, Sergey
    Makhson, Anatoly N.
    Manikhas, Georgiy M.
    Clawson, Alicia
    Bhar, Paul
    McGuire, John R.
    Iglesias, Jose
    CLINICAL BREAST CANCER, 2012, 12 (05) : 313 - 321
  • [47] Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120)
    Ito, Y.
    Aogi, K.
    Masuda, N.
    Ohno, S.
    Oda, T.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Kamigaki, S.
    Ueno, T.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer:A phase II open-label clinical study
    Shanshan Qin
    Hui Yu
    Xianghua Wu
    Zhiguo Luo
    Huijie Wang
    Si Sun
    Mingzhu Huang
    Jia Jin
    Zhonghua Tao
    Jie Qiao
    Yu Feng
    Jialei Wang
    Jianhua Chang
    ChineseJournalofCancerResearch, 2019, 31 (02) : 339 - 348
  • [49] Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study
    Qin, Shanshan
    Yu, Hui
    Wu, Xianghua
    Luo, Zhiguo
    Wang, Huijie
    Sun, Si
    Huang, Mingzhu
    Jin, Jia
    Tao, Zhonghua
    Qiao, Jie
    Feng, Yu
    Wang, Jialei
    Chang, Jianhua
    CHINESE JOURNAL OF CANCER RESEARCH, 2019, 31 (02) : 339 - 348
  • [50] nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial
    Dranitsaris, George
    Coleman, Robert
    Gradishar, William
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (03) : 717 - 724
12345